SECsense Logo

Halozyme Therapeutics 8-K Report: Key Insights on February 11, 2025 Events

$HALO
Form 8-K
Filed on: 2025-02-13
Source
Halozyme Therapeutics 8-K Report: Key Insights on February 11, 2025 Events

Based on the provided XML section of the financial report, here are the key insights and information extracted:

  1. Entity Information:
  • Company Name: Halozyme Therapeutics, Inc.
  • CIK Number: 0001159036
  • SEC File Number: 001-32335
  • State of Incorporation: Delaware (DE)
  • Tax ID: 88-0488686
  • Address: 12390 El Camino Real, San Diego, CA 92130
  • Contact Number: 858-794-8889
  1. Report Type:
  • Filing Type: 8-K (a form used to report major events that shareholders should know about)
  • Filing Date: February 11, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.001
  • Stock Symbol: HALO
  • Exchange: NASDAQ
  1. Period of Reporting:
  • Report Period: The report covers a single day, February 11, 2025.
  1. XML and XBRL Information:
  • The document is formatted in XBRL, which is a standard for electronic communication of financial data.
  • The schema reference indicates that the document follows a specific structure defined in "halo-20250211.xsd".

Summary

This report provides essential information about Halozyme Therapeutics, Inc., including its legal entity details, stock information, and the nature of the filing (8-K). The filing date indicates that it is likely responding to a significant event or development on that specific day.